PCA3 and Familial prostate cancer: Only three studies considered prostate cancer screening programmes, none of which were based purely on PSA testing; one looked at the cost of using prostate cancer antigen 3 (PCA3) urine testing [42], and the other two considered risk scoring approaches [43, 44].